It should be noted that PEITC at the concentration of 5 μM was highly effective against p53−/− CLL cells, and such concentration range is likely achievable in vivo according to pharmacokinetic study [26, 27]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.